BioSpace News Archive

The transaction is comprised of $190 million of cash proceeds at closing plus up to $40 million in milestone payments

Clearbridge BioMedics today announced that it has successfully registered its target cell enrichment device, the ClearCell FX1 system, with the FDA as a Class I Medical Device, for in vitro diagnostic use.

Essential Medical today announced the completion of the 60-day follow up for the MANTA U.S. Pivotal Study.

Instem announced today that Guangdong Lewwin Pharmaceutical Research Institute Co., Ltd. has purchased the Provantis preclinical software solution suite to manage preclinical processes at the Center for Drug Non-clinical Evaluation and Research of Guangdong Institute of Applied Biological Resources in Guangdong, Southern China.

Acceleron today announced positive preliminary results for the first two cohorts in Part 1 of the Phase 2 clinical trial with ACE-083 in patients with facioscapulohumeral dystrophy (FSHD).

A look at Xenon’s key goals for 2018.

Former ASD Healthcare President Neil Herson today joined the Octapharma USA, Inc. executive management team as Senior Vice President of National Accounts and Market Access, bringing nearly 25 years of global pharmaceutical leadership to one of the largest human protein products manufacturers in the world.

The company reported preliminary financial results for the fourth quarter and full year ended December 31, 2017.

Perosphere Pharmaceuticals Inc. announced today that it has appointed Robert S. Langer, Sc.D., founding Chairman of Perosphere’s Scientific Advisory Board and Institute Professor, MIT, to its Board of Directors.

The Company expects revenue for the fourth quarter of 2017 will be between $24.9 and $25.4 million.